×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CMMB – chemomab therapeutics ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CMMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
07:18 am
cmmb
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit [Yahoo! Finance]
Medium
Report
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit [Yahoo! Finance]
12/3
07:00 am
cmmb
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Medium
Report
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
11/19
07:06 am
cmmb
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Yahoo! Finance]
Low
Report
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Yahoo! Finance]
11/19
07:00 am
cmmb
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Low
Report
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
11/15
11:13 am
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
Low
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
11/14
07:09 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/14
07:00 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
10/30
07:00 am
cmmb
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Medium
Report
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/11
06:01 am
cmmb
Form EFFECT Chemomab Therapeutics
Medium
Report
Form EFFECT Chemomab Therapeutics
12/2
04:23 pm
cmmb
Form POS AM Chemomab Therapeutics
Medium
Report
Form POS AM Chemomab Therapeutics
11/29
03:05 pm
cmmb
Form SC 13D/A Chemomab Therapeutics Filed by: Mor George Adi
Neutral
Report
Form SC 13D/A Chemomab Therapeutics Filed by: Mor George Adi
11/21
11:00 am
cmmb
Form SC 13G Chemomab Therapeutics Filed by: Otto Erik
Low
Report
Form SC 13G Chemomab Therapeutics Filed by: Otto Erik
11/18
04:19 pm
cmmb
Form 6-K Chemomab Therapeutics For: Nov 18
Low
Report
Form 6-K Chemomab Therapeutics For: Nov 18
11/15
04:06 pm
cmmb
Form 424B5 Chemomab Therapeutics
Low
Report
Form 424B5 Chemomab Therapeutics
11/14
07:00 am
cmmb
Form 6-K Chemomab Therapeutics For: Nov 14
Low
Report
Form 6-K Chemomab Therapeutics For: Nov 14
10/11
04:01 pm
cmmb
Form 6-K Chemomab Therapeutics For: Oct 11
Medium
Report
Form 6-K Chemomab Therapeutics For: Oct 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: